A healthcare organization is evaluating two Claude-powered AI architectures for a clinical documentation assistant.

Architecture X fails a stated production gate: its 4.2-second average exceeds the required three-second response SLA. It should therefore not remain a qualifying architecture unless it is redesigned and retested before selection. A promise to optimize after deployment is not evidence of compliance.

Architecture Y meets the latency requirement at 2.1 seconds. Its annual inference cost is $180,000 at two million sessions, compared with $360,000 for Architecture X—a difference of $180,000 annually. However, cost alone does not establish suitability. The organization must determine whether Y’s lower quality score causes material omissions, correction effort, clinician dissatisfaction, documentation risk, or reduced workflow productivity.

Option C correctly treats the SLA as a threshold and then analyzes the remaining architecture across cost, efficiency, quality, and productivity. Option A ignores clinical quality. Option B disregards an explicit SLA failure. Option D may eventually be viable, but it introduces routing complexity and leaves unanswered how complex cases are detected, whether X’s latency becomes acceptable for them, and how both paths are evaluated.

The final choice should be gated by clinical-quality evaluation, human review requirements, safety metrics, operational latency, and total annual cost.

Study Guide references/topics: Business-value pillars; performance gates; solution cost; workflow efficiency; quality trade-offs; healthcare architecture evaluation.

===============